Microparticulate β-glucan vaccine conjugates phagocytized by dendritic cells activate both naïve CD4 and CD8 T cells in vitro

Cellular Immunology

Volumn 298, Issue 1-2, 2015, Pages 104-114

  Berner, Vanessa K ^a   duPre, Sally A ^a   Redelman, Doug ^a   Hunter, Kenneth W ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

CD4 T cells; CD8 T cells; Dendritic cells; Vaccine adjuvant; Glucan

Indexed keywords

BETA GLUCAN; CD40 ANTIGEN; CD69 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; OVALBUMIN; T LYMPHOCYTE RECEPTOR; VACCINE; CD86 PROTEIN, MOUSE; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONJUGATE; CONTROLLED STUDY; CROSS PRESENTATION; IN VITRO STUDY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PRIMARY CELL CULTURE; SACCHAROMYCES CEREVISIAE; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD40; ANTIGENS, CD86; BETA-GLUCANS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; PRIMARY CELL CULTURE; SACCHAROMYCES CEREVISIAE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84958634585     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.10.007     Document Type: Article

References (38)

1. Underhill D., Ozinsky A., Hajjar A., Stevens A., Wilson C., Bassetti M., Aderem A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999, 401:811-815.
2. Brown G.D., Herre J., Williams D.L., Willment J.A., Marshall A.S., Gordon S. Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med. 2003, 197:1119-1124.
3. Gantner B.N., Simmons R.M., Canavera S.J., Akira S., Underhill D.M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 2003, 197:1107-1117.
4. Goodridge H.S., Simmons R.M., Underhill D.M. Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J. Immunol. 2007, 178:3107-3115.
5. Huang H., Ostroff G.R., Lee C.K., Agarwal S., Ram S., Rice P.A., Specht C.A., Levitz S.M. Relative contributions of dectin-1 and complement to immune responses to particulate β-glucans. J. Immunol. 2012, 189:312-317.
6. Williams D.L. Overview of (1,3)-β-d-glucan immunobiology. Mediators Inflamm. 1997, 6:247-250.
7. Huang H., Ostroff G.R., Lee C.K., Wang J.P., Specht C.A., Levitz S.M. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect. Immun. 2009, 77:1774-1781.
8. Kim H.S., Hong J.T., Kim Y., Han S.B. Stimulatory effect of β-glucans on immune cells. Immune Netw. 2011, 11:191-195.
9. Herre J., Willment J.A., Gordon S., Brown G.D. The role of Dectin-1 in antifungal immunity. Crit. Rev. Immunol. 2004, 24:193-203.
10. Taylor P.R., Tsoni S.V., Willment J.A., Dennehy K.M., Rosas M., Findon H., Haynes K., Steele C., Botto M., Gordon S., Brown G.D. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat. Immunol. 2007, 8:31-38.
11. Pietrella D., Rachini A., Torosantucci A., Chiani P., Brown A.J., Bistoni F., Costantino P., Mosci P., d'Enfert C., Rappuoli R., Cassone A., Vecchiarelli A. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 2010, 28:1717-1725.
12. Chirigos M.A., Stylos W.A., Schultz R.M., Fullen J.R. Chemical and biological adjuvants capable of potentiating tumor cell vaccine. Cancer Res. 1978, 38:1085-1091.
13. Reynolds J.A., Kastello M.D., Harrington D.G., Crabbs C.L., Peters C.J., Jemski J.V., Scott G.H., Di Luzio N.R. Glucan-induced enhancement of host resistance to selected infectious diseases. Infect. Immun. 1980, 30:51-57.
14. Cook J.A., Holbrook T.W. Immunogenicity of soluble and particulate antigens from Leishmania donovani: effect of glucan as an adjuvant. Infect. Immun. 1983, 40:1038-1043.
15. Sharma A., Haq A.U., Siddiqui M.U., Ahmad S. Immunization of guinea pigs against Entamoeba histolytica using glucan as an adjuvant. Int. J. Immunopharmacol. 1984, 6:483-491.
16. Williams D.L., Yaeger R.G., Pretus H.A., Browder I.W., McNamee R.B., Jones E.L. Immunization against Trypanosoma cruzi: adjuvant effect of glucan. Int. J. Immunopharmacol. 1989, 11:403-410.
17. Hunter K.W., Gault R.A., Berner M.D. Preparation of microparticulate β-glucan from Saccharomyces cerevisiae for use in immune potentiation. Lett. Appl. Microbiol. 2002, 35:267-271.
18. Hunter K.W., duPre S., Redelman D. Microparticulate β-glucan upregulates the expression of B7.1, B7.2, B7-H1, but not B7-DC on cultured murine peritoneal macrophages. Immunol. Lett. 2004, 93:71-78.
19. Berner M.D., Sura M.E., Alves B.A., Hunter K.W. IFN-γ primes macrophages for enhanced TNF-α expression in response to stimulatory and non-stimulatory amounts of microparticulate β-glucan. Immunol. Lett. 2005, 98:122-155.
20. Berner V.K., Sura M.E., Hunter K.W. Conjugation of protein antigen to microparticulate beta-glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations. Appl. Microbiol. Biotechnol. 2008, 80:1053-1061.
21. Huang H., Ostroff G.R., Lee C.K., Specht C.A., Levitz S.M. Characterization and optimization of the glucan particle-based vaccine platform. Clin. Vaccine Immunol. 2013, 20:1585-1591.
22. De Smet R., Demoor T., Verschuere S., Dullaers M., Ostroff G.R., Leclercq G., Allais L., Pilette C., Dierendonck M., De Geest B.G., Cuvelier C.A. β-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination. J. Control. Release 2013, 172:671-678.
23. De Smet R., Allais L., Cuvelier C.A. Recent advances in oral vaccine development: yeast-derived β-glucan particles. Hum. Vaccines Immunother. 2014, 10:1309-1318.
24. lo thymocytes in vivo. Science 1990, 250:1720-1723.
25. Robertson J.M., Jensen P.E., Evavold B.D. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol. 2000, 164:4706-4712.
26. Hemler M.E., Brenner M.B., McLean J.M., Strominger J.L. Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:2172-2175.
27. Lipkowitz S., Greene W.C., Rubin A.L., Novogrodsky A., Stenzel K.H. Expression of receptors for interleukin 2: role in the commitment of T lymphocytes to proliferate. J. Immunol. 1984, 132:31-37.
28. Testi R., Phillips J.H., Lanier L.L. T cell activation via Leu-23 (CD69). J. Immunol. 1989, 143:1123-1128.
29. Ackerman A.L., Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol. 2004, 5:678-684.
30. Amigorena S., Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 2010, 22:109-117.
31. Compeer E.B., Flinsenberg T.W., van der Grein S.G., Boes M. Antigen processing and remodeling of the endosomal pathway: requirements for antigen cross-presentation. Front. Immunol. 2012, 3:1-11.
32. Mantegazza A.R., Magalhaes J.G., Amigorena S., Marks M.S. Presentation of phagocytosed antigens by MHC class I and II. Traffic 2013, 14:135-152.
33. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 1994, 76:17-27.
34. Lutz M.B., Kukutsch N., Ogilvie A.L.J., Rößner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999, 223:77-92.
35. Kapp J.A., Honjo K., Kapp L.M., Xu X.Y., Cozier A., Bucy R.P. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int. Immunol. 2006, 18:1549-1562.
36. Hudig D., Hunter K.W., Diamond W.J., Redelman D. Properties of human blood monocytes. I. CD91 expression and log orthogonal light scatter provide a robust method to identify monocytes that is more accurate than CD14 expression. Cytometry B Clin. Cytom. 2014, 86:111-120.
37. Howland S.W., Tsuji T., Gnjatic S., Old L.J., Ritter G., Wittrup K.D. Inducing efficient cross-priming using antigen-coated yeast particles. J. Immunother. 2008, 31:607-619.
38. Huang H., Ostroff G.R., Lee C.K., Specht C.A., Levitz S.M. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio 2010, 1. e00164-10.